Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coya Therapeutics (COYA) Operating Expenses (2022 - 2025)

Coya Therapeutics (COYA) has disclosed Operating Expenses for 4 consecutive years, with $10.0 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 144.74% to $10.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.5 million through Dec 2025, up 46.61% year-over-year, with the annual reading at $30.5 million for FY2025, 46.61% up from the prior year.
  • Operating Expenses hit $10.0 million in Q4 2025 for Coya Therapeutics, up from $6.0 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $10.0 million in Q4 2025 to a low of $1.7 million in Q1 2022.
  • Historically, Operating Expenses has averaged $4.7 million across 4 years, with a median of $4.1 million in 2023.
  • Biggest five-year swings in Operating Expenses: fell 5.57% in 2023 and later skyrocketed 144.74% in 2025.
  • Year by year, Operating Expenses stood at $2.0 million in 2022, then soared by 108.98% to $4.2 million in 2023, then decreased by 2.5% to $4.1 million in 2024, then surged by 144.74% to $10.0 million in 2025.
  • Business Quant data shows Operating Expenses for COYA at $10.0 million in Q4 2025, $6.0 million in Q3 2025, and $6.6 million in Q2 2025.